Skip to main content
  • Contact Us
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
      • CDMO Intelligence
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas

Breadcrumb

  1. Home
  2. Vantage
  3. Pharmaceutical Companies
  4. Adicet Bio

Evaluate

Thumbnail
February 03, 2023

Gilead spells out allogeneic cell therapy doubts

December 15, 2022

Ash 2022 roundup

Evaluate Vantage's coverage of the Ash 2022 congress.

Article image
Vantage logo
December 14, 2022

Ash 2022 movers – Glycomimetics shakes off its sickle cell past

Meanwhile, there was bad blood between cell therapy players and their investors.

Article image
Vantage logo
December 10, 2022

Ash 2022 – Adicet has a case of déjà vu

Investors got jittery on Friday, and for good reason: like all allogeneic cell therapy players Adicet is seeing patients relapse.

Article image
Vantage logo
November 04, 2022

Ash 2022 preview – Affimed and Aptose score

In oncology settings outside multiple myeloma investors have picked two early winners.

Article image
Vantage logo
October 07, 2022

Nektar and Puretech make strange bedfellows

It is hard to see a combination of the two businesses as much beyond a defensive move in troubled times.

Article image
Vantage logo
October 06, 2022

SITC 2022 preview – cytokines and oral checkpoints

Recently unveiled abstract titles for next month's SITC conference reveal new competition for Incyte’s small-molecule PD-L1 inhibitors.

Article image
Vantage logo
September 26, 2022

Validation for Lava, and a small distraction for Seagen

Article image
Vantage logo
August 03, 2022

It’s official: Roche is a Car-T player

Asset prices fall sufficiently to persuade Roche to sign up to Poseida’s allogeneic cell therapies.

Article image
Vantage logo
July 28, 2022

In8bio finds Adicet a hard act to follow

Article image
Vantage logo
June 13, 2022

EHA 2022 – Crispr’s second off-the-shelf Car-T disappointment

  • Load More

Latest Reports

July 27, 2023

H1 Round Up: The haves and the have-nots

July 21, 2023

ADA/EASL eBook

View more...

Editor's Picks

Vantage logo
July 03, 2023

Astrazeneca and Daiichi’s big reveal disappoints

Vantage logo
July 13, 2023

Pharma finds a way to gain weight

Vantage logo
July 03, 2023

Protagonist investors flake as psoriasis pill disappoints

Vantage logo
June 29, 2023

Approaching datasets for big pharma

Vantage logo
June 27, 2023

Nkarta goes back to basics

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-80-1164-4754

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy
  • Modern Slavery Statement

© Copyright 2023 Evaluate Ltd.

Sign up